期刊文献+

布加综合征患者死亡相关影响因素分析 被引量:1

Influencing Factors of Mortality in Patients with Budd-chiari Syndrome
下载PDF
导出
摘要 目的分析布加综合征(BCS)患者死亡的相关影响因素。方法纳入2008年1月—2012年12月在徐州医学院附属医院介入科住院的BCS患者449例,通过查阅病历收集临床相关资料,并对其行随访调查了解预后情况。采用多因素Logistic回归模型分析其死亡相关影响因素。结果 449例BCS患者死亡32例;单因素分析显示,未死亡组和死亡组患者腹胀、乏力、腹腔积液、黄疸、肝性脑病等因素间差异有统计学意义(P<0.05);Logistic回归模型分析显示肝癌〔OR=72.167,95%CI(11.096,469.363),P<0.05〕、白细胞计数〔OR=1.256,95%CI(1.078,1.463),P<0.05〕、总胆红素〔OR=1.029,95%CI(1.010,1.463),P<0.05〕、不手术〔OR=9.664,95%CI(1.709,54.640),P<0.05〕、生闷气〔OR=3.729,95%CI(1.029,13.512),P<0.05〕、腹腔积液〔OR=41.842,95%CI(2.956,592.191),P<0.05〕和肝性脑病〔OR=32.369,95%CI(1.971,531.439),P<0.05〕为死亡的危险因素。结论存在肝癌、消化道不适、腹腔积液、肝性脑病,白细胞计数、总胆红素水平升高及生闷气、未手术的BCS患者病死率高,需高度重视,应采取相应的措施降低其病死率。 Objective To study the risk factors for death of patients with Budd - Chiari syndrome (BCS). Methods Totally 449 BCS patients treated in the hospital affiliated to Xuzhou Medical College from January 2008 to December 2012 were included in this study. Data retrieved from the medical archives served as the baseline. The data of the prognosis of each patient was collected through follow - ups. Logistic regression analysis was used to explore risk factors for death. Results Among 449 cases of BCS, 32 patients died; univariate analysis indicated that there was significant difference in the incidence rates of abdom- inal distension, fatigue, ascites, jaundice, hepatic encephalopathy and other 20 factors between the death group and the surviv- al group (P 〈0. 05). Logistic regression analysis revealed that hepatocellular carcinoma [ OR = 72. 167, 95% CI ( 11. 096, 469. 363), P 〈 0. 05 ], and white blood cell count [ OR = 1. 256, 95% CI ( 1. 078, 1. 463 ), P 〈 0.05 , total bilirubin [0R=1.029, 95%C1 (1.010, 1.463), P〈0.053, no surgery [OR=9.664, 95%C/ (1.709, 54.640), P〈0.05, frequent sulks [OR=3.729, 95%CI (1.029, 13.512), P〈0.05], ascites OR=41.842, 95%C/ (2.956, 592.191), P 〈0. 05 , hepatic encephalopathy [ OR = 32. 367, 95% CI ( l. 971, 531. 439 ), P 〈 0. 05 , were the risk factors for the mortality of BCS. Conclusion The BCS patients with hepatocellular carcinoma, ascites, hepatic encephalopathy, higher levels of white blood cell and total bilirubin, frequent sulks and receiving no interventional therapy had higher fatality rate, which re- quires great attention. Relative interventions should be made to reduce the fatality rate.
出处 《中国全科医学》 CSCD 北大核心 2014年第5期527-530,共4页 Chinese General Practice
基金 国家自然科学基金资助项目(81172604/H2401) 江苏省2012年度普通高校研究生科研创新计划(CXLX12_0998)
关键词 死亡原因 危险因素 LOGISTIC模型 布加综合征 Cause of death Risk factors Logistic models Budd- chiari syndrome
  • 相关文献

参考文献12

  • 1Valla DC.Primary Budd-Chiari syndrome[J].J Hepatol,2009,50(1):195-203.
  • 2Darwish Murad S,Plessier A,Hernandez-Guerra M,et al.Etiology,management,and outcome of the Budd-Chiari syndrome[J].Annals of Internal Medicine,2009,151(3):167-175.
  • 3Rautou PE,Moucari R,Escolano S,et al.Prognostic indices for Budd-Chiari syndrome:valid for clinical studies but insufficient for individual management[J].American J Gastroenterology,2009,104(5):1140-1146.
  • 4Montano-Loza AJ,Tandon P,Kneteman N,et al.Rotterdam score predicts early mortality in Budd-Chiari syndrome,and surgical shunting prolongs transplant-free survival[J].Alimentary Pharmacol Ther,2009,30(10):1060-1069.
  • 5Shin SH,Chung YH,Suh DD,et al.Characteristic clinical features of hepatocellular carcinoma associated with Budd-Chiari syndrome:evidence of different carcinogenic process from hepatitis B virus-associated hepatocellular carcinoma[J].European Journal of Gastroenterology & Hepatology,2004,16(3):319-324.
  • 6Kage M.Budd-Chiari syndrome and hepatocellular carcinoma[J].Journal of Gastroenterology,2004,39(7):706-707.
  • 7Ren W,Qi X,Yang Z,et al.Prevalence and risk factors of hepatocellular carcinoma in Budd-Chiari syndrome:a systematic review[J].European Journal of Gastroenterology & Hepatology,2013,25(7):830-841.
  • 8Hana Park,Jin Young Yoon,Kyeong Hye Park,Do Young Kim,Sang Hoon Ahn,Kwang-Hyub Han,Chae Yoon Chon,Jun Yong Park.Hepatocellular carcinoma in Budd-Chiari syndrome:A single center experience with long-term follow-up in South Korea[J].World Journal of Gastroenterology,2012,18(16):1946-1952. 被引量:14
  • 9Han G,Qi X,Zhang W,et al.Percutaneous Recanalization for Budd-Chiari syndrome:an 11-year retrospective study on patency and survival in 177 Chinese patients from a single center[J].Radiology,2013,266(2):657-667.
  • 10Seijo S,Plessier A,Hoekstra J,et al.Good long-term outcome of Budd-chiari syndrome with a step-wise management[J].Hepatology,2013,57(5):1962-1968.

二级参考文献24

  • 1Dhiman RK,Saraswat VA,Radhakrishnan S,Parashar A, Agarwal DK,Naik SR. Multiple venous thromboses and membranous obstruction of inferior vena cava in association with hereditary protein C deficiency: a case report. J Gastro- enterol Hepatol 1992; 7: 434-438.
  • 2Nakashima T,Okuda K,Kojiro M,Jimi A,Yamaguchi R, Sakamoto K,Ikari T. Pathology of hepatocellular carcinoma in Japan. 232 Consecutive cases autopsied in ten years. Can- cer 1983; 51: 863-877.
  • 3Matsui S,Ichida T,Watanabe M,Sugitani S,Suda T,Taka- hashi T,Asakura H. Clinical features and etiology of hepa- tocellular carcinoma arising in patients with membranous obstruction of the inferior vena cava: in reference to hepatitis viral infection. J Gastroenterol Hepatol 2000; 15: 1205-1211.
  • 4Tanaka M,Wanless IR. Pathology of the liver in Budd-Chi- ari syndrome: portal vein thrombosis and the histogenesis of veno-centric cirrhosis,veno-portal cirrhosis,and large regen- erative nodules. Hepatology 1998; 27: 488-496.
  • 5Okuda K. Inferior vena cava thrombosis at its hepatic por- tion (obliterative hepatocavopathy). Semin Liver Dis 2002; 22: 15-26.
  • 6Gwon D,Ko GY,Yoon HK,Sung KB,Kim JH,Lee SS,Lee JM,Ohm JY,Shin JH,Song HY. Hepatocellular carcinoma associated with membranous obstruction of the inferior vena cava: incidence,characteristics,and risk factors and clinical efficacy of TACE. Radiology 2010; 254: 617-626.
  • 7Moucari R,Rautou PE,Cazals-Hatem D,Geara A,Bureau C, Consigny Y,Francoz C,Denninger MH,Vilgrain V,Belghiti J,Durand F,Valla D,Plessier A. Hepatocellular carcinoma in Budd-Chiari syndrome: characteristics and risk factors. Gut 2008; 57: 828-835.
  • 8Eapen CE,Mammen T,Moses V,Shyamkumar NK. Chang- ing profile of Budd Chiari syndrome in India. Indian J Gastro- enterol 2007; 26: 77-81.
  • 9Kew MC,McKnight A,Hodkinson J,Bukofzer S,Esser JD. The role of membranous obstruction of the inferior vena cava in the etiology of hepatocellular carcinoma in Southern African blacks. Hepatology 1989; 9: 121-125.
  • 10Rector WG,Xu YH,Goldstein L,Peters RL,Reynolds TB. Membranous obstruction of the inferior vena cava in the United States. Medicine (Baltimore) 1985; 64: 134-143.

共引文献13

同被引文献12

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部